Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLY pediatric pegunigalsidase alfa study in Fabry disease
2022-503128-29-00Phase 3Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 6
01
Overview
Phase 3, open-label trial of pegunigalsidase alfa in Fabry disease (FD) (3 cohorts), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Treatment-emergent adverse events, Infusion-related reactions and 31 more. Planned start Oct 2024; status: authorised.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2022-503128-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503128-29-00.